source
- Angelini to buy Catalyst in $4B play for rare neuro drugsThe acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider market access in the U.S.BioPharma Dive · 2mo ago↗ source
- Entrada shares dive as Duchenne results disappointWhile the company claimed a victory, analysts said data from a Phase 1/2 study fell short of expectations. Entrada shares subsequently tumbled more than 50%.BioPharma Dive · 2mo ago↗ source
- Entrada stock falls on Duchenne data; Wegovy expands accessPlus, news about BioCryst, GSK and Roche. 🙃 Entrada’s Duchenne drug disappoints: The biotech reported initial data in six patients who received the low dose of its exon 44 skipping drug ...Endpoints · 2mo ago